{"entity":{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","aka":["BrightPath Bio","GreenPeptide"],"tldr":"BrightPath Biotherapeutics is a Japanese company making ready-made immune cell therapies grown from stem cells. Its lead product, BP2202, uses engineered natural killer T cells aimed at the BCMA protein on myeloma cells and is in a first US trial for myeloma that has returned or stopped responding.","summary":"BrightPath Biotherapeutics Co., Ltd. (Japanese name ブライトパス・バイオ), headquartered in Kojimachi, Chiyoda-ku, Tokyo, with research laboratories at the Life Innovation Center in Kawasaki, was established on 8 May 2003 in Kurume, Fukuoka, according to the company, and listed on the Tokyo Stock Exchange Mothers market in October 2015; it took its present name in July 2017. Earlier work centred on cancer peptide vaccines (ITK-1 in castration-resistant prostate cancer and GRN-1201). Its current platform is iPS-NKT: allogeneic, off-the-shelf natural killer T cells regenerated from a master iPS cell bank. BP2202 is a BCMA-targeted CAR-iNKT cell therapy derived from iPS cells, granted FDA orphan drug designation for multiple myeloma in July 2025; a US open-label, multicentre, dose-escalation phase 1 study in relapsed or refractory multiple myeloma is registered (NCT07667868). The pipeline also lists HER2-targeted CAR-iNKT cells and antibody programmes. Its first registered cancer trial under this sponsor name, NCT07667868, was posted on ClinicalTrials.gov in June 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.brightpathbio.com/"},{"label":"BP2202 programme page (Japanese)","url":"https://www.brightpathbio.com/pipeline/bp2202.html"},{"label":"ClinicalTrials.gov: phase 1 trial of BP2202 in relapsed or refractory multiple myeloma (NCT07667868)","url":"https://clinicaltrials.gov/study/NCT07667868"}],"tags":[],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":["cell-therapy","immunotherapy"],"technologies":["allogeneic-cell-therapy"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: brightpathbio.com Japanese home, company outline (founding date, addresses, history) and BP2202 pages. The English pages returned 404.","The stock code was not confirmed on the pages read, so no ticker is given. Earlier vaccine trials may have been registered under the former name GreenPeptide; that history was not checked."," OnCo has no iPSC-derived NKT technology record, so only the allogeneic cell therapy record is linked."],"hq":"Tokyo","country":"JP","companyType":"cell-therapy","website":"https://www.brightpathbio.com/","founded":2003,"stage":"public","investors":[],"funding":[]},"route":"/companies/brightpath-biotherapeutics/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}]}}